In today’s briefing:
- GDMC nets US$21M in Series A for its next-gen advanced genetic therapies | e27
- China Healthcare Weekly (Feb.2) – US Strike on China CXOs, CSPC Innovation, Peach Picking Period
- Intuitive Surgical: Are They Capitalizing Enough On The Expanded Adoption Of Robotic Surgery? – Major Drivers
GDMC nets US$21M in Series A for its next-gen advanced genetic therapies | e27
- Genetic Design and Manufacturing Corporation (GDMC), a design and manufacturing organisation focusing on next-generation advanced genetic therapies, has secured US$21 million in Series A funding.
- Asian private equity firm Celadon Partners led the round, which also saw participation from WI Harper Group, SEEDS Capital, and NSG Ventures.
- The funds will be used to accelerate novel technology and process efficiency improvements to drive greater manufacturing cost reductions for partners who aim to advance medicines through clinical trials and towards commercialisation.
China Healthcare Weekly (Feb.2) – US Strike on China CXOs, CSPC Innovation, Peach Picking Period
- If there’s ultimately substantial negative policies in the field of biopharmaceuticals between China and US, APIs will be the segment with the highest risk. But CXO would also be affected.
- Now we have entered the harvest period after the previous peak of financing round in China’s biotech industry, which has become a concentrated “peach picking period” for foreign pharmaceutical enterprises.
- Considering the low market sentiment, we’re cautious on companies with high valuation elasticity before they come up with convincing products. So, we don’t recommend investors rush to bottom-fish CSPC Innovation.
Intuitive Surgical: Are They Capitalizing Enough On The Expanded Adoption Of Robotic Surgery? – Major Drivers
- Intuitive Surgical enjoyed a strong 2023, seeing increasing use of its platforms in hospitals and improvement in system capacity to manage growth.
- Full year growth for procedures was 22%, led by general surgery in the US and diverse growth in international markets such as Germany, France, the UK, and Ireland.
- However, there was a slowdown in growth across bariatric procedures due to the use of GLP-1 drugs for obesity.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
